Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul;41(7):489-498.
doi: 10.1038/s41440-018-0041-5. Epub 2018 Apr 13.

Antihypertensive effect of etamicastat in dopamine D2 receptor-deficient mice

Ines Armando  1 , Laureano D Asico  2 , Xiaoyan Wang  2 , John E Jones  2 , Maria Paula Serrão  3 , Santiago Cuevas  2 , David K Grandy  4 , Patricio Soares-da-Silva  3 , Pedro A Jose  2   5
Affiliations

Antihypertensive effect of etamicastat in dopamine D2 receptor-deficient mice

Ines Armando et al. Hypertens Res. 2018 Jul.

Abstract

Abnormalities of the D2R gene (DRD2) play a role in the pathogenesis of human essential hypertension; variants of the DRD2 have been reported to be associated with hypertension. Disruption of Drd2 (D2-/-) in mice increases blood pressure. The hypertension of D2-/- mice has been related, in part, to increased sympathetic activity, renal oxidative stress, and renal endothelin B receptor (ETBR) expression. We tested in D2-/- mice the effect of etamicastat, a reversible peripheral inhibitor of dopamine-β-hydroxylase that reduces the biosynthesis of norepinephrine from dopamine and decreases sympathetic nerve activity. Blood pressure was measured in anesthetized D2-/- mice treated with etamicastat by gavage, (10 mg/kg), conscious D2-/- mice, and D2+/+ littermates, and mice with the D2R selectively silenced in the kidney, treated with etamicastat in the drinking water (10 mg/kg per day). Tissue and urinary catecholamines and renal expression of selected G protein-coupled receptors, enzymes related to the production of reactive oxygen species, and sodium transporters were also measured. Etamicastat decreased blood pressure both in anesthetized and conscious D2-/- mice and mice with renal-selective silencing of D2R to levels similar or close to those measured in D2+/+ littermates. Etamicastat decreased cardiac and renal norepinephrine and increased cardiac and urinary dopamine levels in D2-/- mice. It also normalized the increased renal protein expressions of ETBR, NADPH oxidase isoenzymes, and urinary 8-isoprostane, as well as renal NHE3 and NCC, and increased the renal expression of D1R but not D5R in D2-/- mice. In conclusion, etamicastat is effective in normalizing the increased blood pressure and some of the abnormal renal biochemical alterations of D2-/- mice.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

Figures

Figure 1.
Figure 1.. Effect of etamicastat on blood pressure in anesthetized and conscious D2+/+ and D2−/−mice.
A. Etamicastat (Etam, 1O mg/kg) or vehicle was administered by gavage. Blood pressure was measured under pentobarbital anesthesia 9 and 18 h after etamicastat administration in different groups of D2+/+ and D2−/− mice. n=4–5/group; *P<O.O5 vs all others, one-way ANOVA followed by Holm-Sidak test B. Etamicastat (Etam, 1O mg/kg/day) or vehicle was added to the drinking water. Blood pressure was measured by telemetry in conscious mice. Values are means of 6 h measurements (one per h). D2+/+ n=5; D2−/− n=4. *P<O.O5 vs D2+/+ one-way ANOVA followed by Holm-Sidak test. C. Etamicastat (1O or 5O mg/kg/day) was added to the drinking water. Blood pressure was measured by telemetry in conscious mice. Values shown are means of 6 hr measurements during the day and night (one reading per h after 5 days on each treatment). D2+/+ n=4; D2−/− n=3. * P<O.O5 vs D2−/− vehicle or same treatment D2+/+, two-way ANOVA followed by Holm-Sidak test.
Figure 2.
Figure 2.. Effect of etamicastat on blood pressure in mice with renal-selective silencing of the D2R.
Renal cortical Drd2 was silenced by the renal subcapsular infusion of Drd2 siRNA, via an osmotic minipump for seven days in uninephrectomized adult male C57BL/6J mice (see Methods). Etamicastat (Etam, 1O mg/kg/day in the drinking water) was started immediately after pump implantation. Blood pressure was measured under anesthesia before and 7 days after pump implantation. n=5/group; *P<O.O5 vs all others; one-way ANOVA followed by Holm-Sidak test. Two-way ANOVA positive for effect of D2R siRNA and etamicastat.
Figure 3.
Figure 3.. Effect of etamicastat on norepinephrine (NE) and dopamine (DA) content in heart, and urine of D2+/+ and D2−/− mice.
Etamicastat (Etam, 10 mg/kg/dose) or vehicle was administered by gavage. Urine collection was started immediately after gavage and lasted for 18 h. Tissues were collected after ending the urine collection. Urine and tissue NE (A) and DA (B) were measured by HPLC-ED, n=5–8/group. The tissue or urine DA/NE ratio (C) was calculated. *P<0.05 vs all others; **P<0.05 vs same group vehicle-treated mice; one-way ANOVA followed by Holm-Sidak test.
Figure 4.
Figure 4.. Effect of etamicastat on the renal expression of dopamine, angiotensin II type 1, and endothelin B receptors.
Etamicastat (Etam, 10 mg/kg/day) was added to the drinking water for 5 days. Receptor expression was determined by immunoblotting. A. Receptor expression in vehicle-treated mice; n=8– 10/group; B. Receptor expression in etamicastat-treated mice; n=4–5/group. *P<0.05 vs D2+/+ mice; one-way ANOVA followed by Holm-Sidak test.
Figure 5.
Figure 5.. Effect of etamicastat on the expression of ROS-related enzymes.
Etamicastat (Etam, 10 mg/kg/day) was added to the drinking water for 5 days. Expression of HO-1, HO-2, NOX1, NOX2, and NOX4 was determined by immunoblotting. A. Expression of HO and NOX isoforms in vehicle-treated mice; n=5/group; B. Expression of HO and NOX isoforms in etamicastat-treated mice; n=5/group. *P<0.05 vs D2+/+ mice; one-way ANOVA followed by Holm-Sidak test.
Figure 6.
Figure 6.. Effect of etamicastat on the expression of renal sodium transporters, exchangers, channels, and pump.
Etamicastat (Etam, 10 mg/kg/day) was added to the drinking water for 5 days. Renal expression of sodium transporters, exchangers, channels, and pump was determined by immunoblotting. A. Expression in vehicle-treated mice; n=4–5/group; B. Expression in etamicastat-treated mice; n=4/group. *P<0.05 vs D2+/+ mice; one-way ANOVA followed by Holm-Sidak test.
See this image and copyright information in PMC

References

    1. Beliaev A, Learmonth DA, Soares-da-Silva P. Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine beta hydroxylase. JMed Chem. 2006: 49:1191–1197 - PubMed
    1. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014. evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014: 311:507–520. - PubMed
    1. Igreja B, Pires NM, Bonifacio MJ, Loureiro AI, Fernandes-Lopes C, Wright LC, Soares-da-Silva P. Blood pressure-decreasing effect of etamicastat alone and in combination with antihypertensive drugs in the spontaneously hypertensive rat. Hypertens Res 2015;38:30–38. - PubMed
    1. Igreja B, Wright L, Soares-da-Silva P. Sustained high blood pressure reduction with etamicastat, a selective peripheral dopamine-β-hydroxylase inhibitor. J Am Soc Hypertens 2016;10:207–216.. - PubMed
    1. Almeida L, Nunes T, Costa R, Rocha JF, Vaz-da-Silva M, Soares-da-Silva P. Etamicastat, a novel dopamine ß-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension. Clin Ther. 2013:35:1983–1996. - PubMed

MeSH terms